Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
StemEx · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| StemEx | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| StemEx® | DRUG | The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit. |
Inclusion Criteria: 1. Clinical diagnosis of AML or ALL: CR2 or subsequent complete remission (CR) or CR1 with high-risk features or relapse with \< 10% blasts in BM and no circulating blasts. 2. Clinical diagnosis of CML: in CP1 (Chronic Phase 1) and resistant or intolerant to Gleevec or in CP2 or...
StemEx is an investigational small molecule being studied for the treatment of hematologic malignancies, including acute myeloid leukemia, lymphoid leukemia, chronic myeloid leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, and myelodysplastic syndromes. It is administered following myeloablative therapy in patients with high-risk disease.
StemEx is being developed by Teva Pharmaceutical Industries Limited, whose stock trades under the ticker TEVA. The drug is currently in clinical development for hematologic malignancies.
StemEx is in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug that has not been approved by regulatory authorities.
StemEx has one completed clinical trial, NCT00469729, which evaluated its efficacy and safety in subjects with high-risk hematologic malignancies following myeloablative therapy. The trial enrolled 101 participants across the United States, Hungary, Israel, Italy, and Spain.
StemEx is the name used in clinical trials for this investigational therapy. No alternative names have been reported for this drug in the available clinical trial information.